After statins, the next leading class of medications for managing cholesterol are PCSK9 inhibitors. These highly effective agents help the body pull excess cholesterol from the blood, but unlike statins, which are available as oral agents, PCSK9 inhibitors can only be administered as shots, creating barriers to their use. Now, a new study describes an orally administered small-molecule drug that reduces PCSK9 levels and lowers cholesterol in animal models by 70%. The findings represent a previously unrecognized strategy for managing cholesterol and may also impact cancer treatments.